Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MYCN in neuronal tumours.

Manfred Schwab1

  • 1Department of Tumour Genetics-B030, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, Heidelberg D-69120, Germany. m.schwab@dkfz.de

Cancer Letters
|March 12, 2004
PubMed
Summary

Amplified MYCN oncogene, a transcription factor, is linked to neuroectodermal tumors. Its presence in neuroblastoma indicates a poor prognosis, making MYCN status crucial for cancer stratification.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A journey to excellence: Disseminating groundbreaking discoveries in oncology research.

Cancer letters·2023
Same author

MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma.

Oncotarget·2016
Same author

Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.

Clinical cancer research : an official journal of the American Association for Cancer Research·2014
Same author

Stronger prognostic power of the CpG island methylator phenotype than methylation of individual genes in neuroblastomas.

Japanese journal of clinical oncology·2013
Same author

Instability at the FRA8I common fragile site disrupts the genomic integrity of the KIAA0146, CEBPD and PRKDC genes in colorectal cancer.

Cancer letters·2013
Same author

Low p14ARF expression in neuroblastoma cells is associated with repressed histone mark status, and enforced expression induces growth arrest and apoptosis.

Human molecular genetics·2013

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • MYCN is a member of the MYC oncogene family, encoding transcription factors involved in various cancers.
  • Unlike other MYC oncogenes, MYCN alterations are specifically associated with neuroectodermal-derived tumors.
  • Increased MYCN gene dosage, often via amplification, is a common activation mechanism.

Purpose of the Study:

  • To investigate the role of MYCN gene dosage in cancer development and prognosis.
  • To highlight the significance of MYCN amplification in neuroblastoma stratification.

Main Methods:

  • Analysis of MYCN gene dosage in tumor samples.
  • Correlation of MYCN status with clinical outcomes and cancer types.

Main Results:

  • MYCN amplification is a key mechanism in neuroectodermal tumors.
  • Amplified MYCN is a significant indicator of poor prognosis in neuroblastoma.
  • Normal MYCN gene dosage correlates with better outcomes in localized neuroblastoma.

Conclusions:

  • MYCN amplification is a critical oncogenic event in neuroblastoma.
  • MYCN gene status is an established and vital biomarker for neuroblastoma patient stratification worldwide.

Related Experiment Videos